Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pemetrexed. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GART known ✓ | P22102 | 10/20 | 0.76 |
| ▸ | DHFR known ✓ | P00374 | 6/20 | 0.76 |
| ▸ | TYMS known ✓ | P04818 | 5/20 | 0.76 |
| ▸ | FOLR1 | P15328 | 4/20 | 0.76 |
| ▸ | SLC46A1 | Q96NT5 | 4/20 | 0.76 |
| ▸ | ATIC | P31939 | 3/20 | 0.76 |
| ▸ | FOLR2 | P14207 | 3/20 | 0.76 |
| ▸ | SLC19A1 | P41440 | 3/20 | 0.76 |
| ▸ | SHMT1 | P34896 | 2/20 | 0.76 |
| ▸ | FRK | P42685 | 1/20 | 0.76 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pemetrexed SCHEMBL3760710 | 1.00 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL1934793 | 1.00 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL124663 | 1.00 | GART (0.76) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL577951 | 0.99 | GART (0.75) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL21600667 | 0.99 | GART (0.75) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL15569564 | 0.99 | GART (0.75) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL2549428 | 0.99 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL7968 | 0.99 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL7969 | 0.99 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 | |
| Pemetrexed SCHEMBL6034765 | 0.99 | GART (0.77) | GARTDHFRTYMSFOLR1SLC46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117717564-A | Application of antisense oligonucleotide in preparing medicine for treating lung cancer | 北京悦康科创医药科技股份有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-115608309-A | Production method of high-purity pemetrexed disodium | 连云港贵科药业有限公司 | 2023-01-17 | — | — | CN | claimed |
| CN-114206392-A | Immunomodulatory agent antibody drug conjugates and uses thereof | 苏特罗生物制药公司 | 2022-03-18 | — | — | CN | claimed |
| CN-106466299-B | Blank liposome taking ginsenoside as membrane material, preparation method and application thereof | 上海本素医药科技有限公司 | 2021-09-28 | — | — | CN | claimed |
| CN-108135168-B | CCR2 modulators | 凯莫森特里克斯股份有限公司 | 2021-07-20 | — | — | CN | claimed |
| CN-111060615-A | Method for detecting additive in pemetrexed disodium product | 上海微谱化工技术服务有限公司 | 2020-04-24 | — | — | CN | claimed |
| WO-2019244965-A1 | PEMETREXED SODIUM INJECTION SOLUTION FORMULATION AND MANUFACTURING METHOD THEREFOR | 日本化薬株式会社 | 2019-12-26 | — | — | WO | claimed |
| US-9090633-B2 | Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2015-07-28 | — | — | US | claimed |
| EP-2648509-B1 | SUBSTITUTED 4-(ARYLAMINO) SELENOPHENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD (IN) | 2015-04-29 | — | — | EP | claimed |
| US-20140066463-A1 | SOLID FORMS OF PEMETREXED | DR. REDDY'S LABORATORIES, INC. (US) | 2014-03-06 | — | — | US | claimed |
| US-20130287767-A1 | SUBSTITUTED 4-(ARYLAMINO) SELENOPHENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2013-10-31 | — | — | US | claimed |
| EP-2648509-A2 | SUBSTITUTED 4-(ARYLAMINO) SELENOPHENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Kasina Laila Innova Pharmaceuticals Private Ltd. (IN) | 2013-10-16 | — | — | EP | claimed |
| US-8507508-B2 | Solid forms of pemetrexed | DR. REDDY'S LABORATORIES LIMITED (IN) | 2013-08-13 | — | — | US | claimed |
| WO-2012077135-A2 | SUBSTITUTED 4-(ARYLAMINO) SELENOPHENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2012-06-14 | — | — | WO | claimed |
| US-20100063072-A1 | SOLID FORMS OF PEMETREXED | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | US | claimed |
| EP-2129674-A2 | SOLID FORMS OF PEMETREXED | Dr. Reddy's Laboratories Ltd. (IN) | 2009-12-09 | — | — | EP | claimed |
| WO-2008124485-A2 | SOLID FORMS OF PEMETREXED | DR. REDDY'S LABORATORIES LTD. (IN) | 2008-10-16 | — | — | WO | claimed |
| CN-113453684-B | CSF1R inhibitors for the treatment of cancer | 德西费拉制药有限责任公司 | 2024-05-14 | — | — | CN | disclosed |
| US-6013828-A | Processes and intermediates useful to make antifolates | ELI LILLY AND COMPANY (US) | 2000-01-11 | — | — | US | disclosed |
| EP-0905128-A1 | Processes and intermediates useful to make antifolates | ELI LILLY AND COMPANY (US) | 1999-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130287767-A1 | SUBSTITUTED 4-(ARYLAMINO) SELENOPHENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | SELENOI, VHL, DPYD | GART 2842/4885DHFR 97/4885TYMS 581/4885 |
| US-20140066463-A1 | SOLID FORMS OF PEMETREXED | TYMP, TYMS, HPRT1 | GART 21/4885DHFR 10/4885TYMS 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.